Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1978 1
1980 1
1981 1
1982 2
1983 2
1984 2
1985 3
1986 3
1987 4
1988 5
1989 11
1990 18
1991 19
1992 31
1993 34
1994 35
1995 47
1996 61
1997 76
1998 63
1999 78
2000 86
2001 94
2002 97
2003 118
2004 124
2005 127
2006 95
2007 104
2008 120
2009 106
2010 139
2011 134
2012 133
2013 112
2014 100
2015 100
2016 80
2017 96
2018 83
2019 92
2020 77
2021 73
2022 53
2023 44
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

2,555 results

Results by year

Filters applied: . Clear all
Page 1
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. Bone HG, et al. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22. Lancet Diabetes Endocrinol. 2017. PMID: 28546097 Clinical Trial.
The yearly exposure-adjusted participant incidence of adverse events for all individuals receiving denosumab decreased from 165.3 to 95.9 per 100 participant-years over the course of 10 years. Serious adverse event rates were generally stable over time, varying between 11. …
The yearly exposure-adjusted participant incidence of adverse events for all individuals receiving denosumab decreased from 165.3 to 95.9 pe …
Menopause in CKD.
Vellanki K, Hou S. Vellanki K, et al. Am J Kidney Dis. 2018 May;71(5):710-719. doi: 10.1053/j.ajkd.2017.12.019. Epub 2018 Mar 9. Am J Kidney Dis. 2018. PMID: 29530509 Review.
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.
Marshall D, Johnell O, Wedel H. Marshall D, et al. BMJ. 1996 May 18;312(7041):1254-9. doi: 10.1136/bmj.312.7041.1254. BMJ. 1996. PMID: 8634613 Free PMC article.
MAIN OUTCOME MEASURES: Relative risk of fracture for a decrease in bone mineral density of one standard deviation below age adjusted mean. RESULTS: All measuring sites had similar predictive abilities (relative risk 1.5 (95% confidence interval 1.4 to 1.6)) for decrease in …
MAIN OUTCOME MEASURES: Relative risk of fracture for a decrease in bone mineral density of one standard deviation below age adjusted mean. R …
Update on the epidemiology of osteoporosis.
Wolf RL, Zmuda JM, Stone KL, Cauley JA. Wolf RL, et al. Curr Rheumatol Rep. 2000 Feb;2(1):74-86. doi: 10.1007/s11926-996-0072-9. Curr Rheumatol Rep. 2000. PMID: 11123043 Review.
Osteoporosis: preventive strategies.
Kulak CA, Bilezikian JP. Kulak CA, et al. Int J Fertil Womens Med. 1998 Mar-Apr;43(2):56-64. Int J Fertil Womens Med. 1998. PMID: 9609204 Review.
Management of primary osteoporosis.
Body JJ. Body JJ. Acta Clin Belg. 2002 Sep-Oct;57(5):277-83. doi: 10.1179/acb.2002.054. Acta Clin Belg. 2002. PMID: 12534136 Review.
2,555 results